NMS Group certified as “Workplace that promotes health initiatives” again in 2022
Nerviano, 05/04/2023 NMS Group certificato di nuovo come “Luogo di lavoro che promuove salute” nel 2022 NMS group dal 2017 aderisce con gran orgoglio al programma WHP , progetto di Regione Lombardia e ATS Città Metropolitana di Milano che si pone come obiettivo la promozione della salute e il benessere nei luoghi di lavoro. Anche […]
Nerviano Medical Sciences S.r.l. to Present New Preclinical Data for NMS-812 and NMS-0963 at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Nerviano Medical Sciences S.r.l. to Present New Preclinical Data for NMS-812 and NMS-0963 at the American Association for Cancer Research (AACR) 2023 Annual Meeting NMS-812: A potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the ISR entered FIH clinical trial mid-2022 NMS-0963: A selective and orally available Syk inhibitor with promising preclinical activity in […]
Nerviano Medical Sciences S.r.l. Announces Clinical Data on NMS-03592088 selected for Oral Presentation at AACR Annual Meeting 2023
NERVIANO, 4 April 2023 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the Phase I/II clinical study of NMS-03592088 in Acute Myeloid Leukemia will be reported in an oral presentation by Dr. […]
NMS-0963 is a novel potent, selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma
G. Saturno, M. Modugno, P. Orsini, G. Cervi, L. Buffa, I. Motto, N. Avanzi, M. Montemartini, F. Gasparri, G. Texido, A. Galvani, A. Isacchi AACR Annual Meeting 2023; 2023 April 14-19; Orlando, FL. –Abstract 4036 Cancer Res (2023) 83 (7_Supplement)
NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong antitumor activity as single agent and in combination in preclinical models.
C. Perrera, M. Pulici, P. Banfi, N. Avanzi, D. Carenzi, D. Casero, A. Ciavolella, L. Gianellini, F. Gasparri, G. Saturno, B. Valsasina, E. Ardini, A. Montagnoli, A. Galvani, A. Isacchi AACR Annual Meeting 2023; 2023 April 14-19; Orlando, FL. –Abstract 1615 Cancer Res (2023) 83 (7_Supplement)
Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-inclass potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.
L. Rimassa, M. Reig, S. Damian, D. Roberti, S. Maruzzelli, F. Gasparri, P. Ghioni, M.T. De Pietro, T. Pressiani, M. Sanduzzi Zamparelli, M. Duca, A. Montagnoli, A. Galvani, E. Ardini, A. Isacchi, C. Davite, P. Crivori, L. Mahnke 2023 ASCO Annual Meeting; June 2-6, 2023; at Chicago, IL. –Slide deck –Abstract TPS4185 Journal of Clinical […]
Initial Results from 2 Phase I Studies of NMS-03305293, a Selective PARP1 Inhibitor
M. Geurts; D. Gramatzki; S. Merler; M. Duca; F. Girardi; U. T. Sener; D. Roberti; G. Saturno; P. Crivori; A. Montagnoli; L. Mahnke; S. Fu; P. Gaviani; K. A. Jaeckle; J. Zhang; Y. Shi; V. Guarneri; M. Weller; S. H. Kizilbash; M. J. van den Bent; M. Milella; S. Damian AACR-NCI-EORTC International Conference on Molecular […]
Nerviano Medical Sciences Appointed Anders Elm Pedersen, MD, PhD, DMSc, as Senior Medical Director to accelerate further the Global Clinical Development progress
NERVIANO, IT March 1st 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Anders Elm Pedersen MD, PhD, DMSc., has joined Global Clinical Development as Senior Medical Director to lead […]
Nerviano Medical Sciences Appointed Gergely Balint MSc to Accelerate MPS1 Inhibitor Asset Development
NERVIANO, IT and BOSTON, Mass, 01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Gergely Balint, MSc, has joined the Global Asset Leadership Team to lead the development […]
Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset – Terrence West, MBA, joins as New Business, Virtual CEO
NERVIANO, IT and BOSTON, Mass, January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor […]